Free and bound choline blood levels after phosphatidylcholine
Clinical and laboratory research in the field of central nervous system cholinergic pharmacology has been seriously hampered by the lack of a long-lasting cholinomimetic agent that is active in the brain. Based on the contention that increased levels of choline will increase the concentration of choline in the brain since the choline transport system across the blood brain barrier (KT approximately 440 ktM) is not saturated by the normal plasma choline concentration of 10 to 20 ,uM,6 Haubrich et al.") and Wurtman et a1.5' 20 suggested the use of large doses of choline to promote acetylcholine (ACh) synthesis. Systemic administration of choline may lead to a rise in choline levels in the brain,5' 10 but a resultant elevation in levels and utilization of ACh is controversial (for review, see Jenden").
Recently choline has been partially superseded by the use of phosphatidylcholine* (PCh), which does not give rise to the strong "fishy" odor obtained after choline treatment .4' " PCh has been reported to be beneficial in patients with tardive dyskinesia8' 22 and is undergoing clinical evaluation in a number of other diseases. 2-4, 7, 18, 19 Since the clinical use of the *Although the term lecithin has recently been used in reports of investigations of phosphatidylcholine therapy, lecithin has long been used to indicate an impure mixture of phosphatides. We therefore use phosphatidyl to more accurately identify the compound under investigation. [2H9]-PCh was labeled in the choline moiety by predeuteration of the methyl groups. Free choline was hydrolyzed from the lipids by incubation in 1N KOH for 1 hr at 95°. Choline was isolated by ion-pair extraction with dipicrylamine into dichloromethane and measured by gas chromatographymass spectrometry as previously described." Choline was also measured by gas chromatography using a nitrogen detector with homocholine (3-hydroxypropyltrimethylammonium iodide) as the internal standard after extraction as described by Kosh et al.17 The results of the two assays were almost identical with correlation coefficients of 0.98 for choline in both plasma and erythrocytes.
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Results
Oral doses of 15 gm PCh/70 kg body weight increased plasma choline concentrations to levels three to four times those before treatment (Fig. 1, A) . Increased concentrations were apparent 1 hr after treatment in all subjects.
Effects of PCh on free and bound choline 485 Plasma choline levels peaked between 3 and 4 hr after PCh. The duration of the peak plasma choline level varied among the subjects, e.g., in two subjects there was a well-defined peak while in two others there was a plateau between 3 and 8 hr after treatment. Plasma choline concentrations were near normal, although still slightly elevated, 24 hr after treatment.
Erythrocyte choline concentrations rose in approximate parallel to the rise in plasma choline (Fig. 1, B) , but the increase of choline in erythrocytes was delayed relative to the plasma choline and reached maximum concentrations between 4 and 6 hr after PCh. The results from one subject were omitted from the calculations because his initial erythrocyte choline concentration was 170 ktM, approximately 10 times that of the other subjects. The high erythrocyte choline level was confirmed in a repeat determination 1 mo later. The cause of this abnormally high level is under investigation.
The ratio of the choline concentration in erythrocytes to that in plasma is shown in Fig.  2 . This indicates that, although the intracellular erythrocyte choline concentration rose, it did not do so to the same extent as plasma choline.
Lipid bound choline in the plasma did not change after PCh (Fig. 1, B) .
Discussion
These results demonstrate that, in man, PCh raises plasma choline concentration for a longer period than an equimolar dose of choline. The only side effect noted was mild nausea in two subjects approximately 6 hr after treatment. The extended effect of, and minimal side effects attributed to, PCh suggest that it is clinically preferable to choline as a means of elevating plasma choline levels.
The only cell easily accessible for measuring intracellular choline concentration in man is the erythrocyte. PCh induced prolonged elevation of erythrocyte choline concentration to much the same extent as plasma choline. This is presumably a direct result of the increased plasma choline concentration since the erythrocyte has a transport system with a relatively low affinity for choline (40 AM) that is not saturated by the normal plasma choline concentration of approximately 10 M. These results in erythrocytes indicate that at least one intracellular pool of choline increases after PCh. As shown in Fig.  2 , however, the intracellular erythrocyte choline concentration did not rise to the same degree as plasma choline. The ratio of erythrocyte choline to the plasma choline level may be a useful index for monitoring intracellular choline changes after PCh or choline. The blood brain barrier also has a low affinity for choline (KT = 440 iuM) so that choline transport from the plasma into the brain should also be increased by PCh treatment.6 Whether or not increased brain choline will alter the activity of cholinergic neurons remains to be determined. Although this hypothesis remains unresolved, choline loading may have a greater effect in pathologic states where there is evidence of cholinergic hypofunction. The beneficial effects of PCh therapy reported4 and the prolonged increase in choline levels, with minimal side effects, following PCh suggest that it is a drug of choice for promoting cholinergic function by precursor loading.
